Live from #AACR26: We’re presenting new data highlighting the efficacy and safety of our ROS1 inhibitor in TKI-naive and TKI-pretreated patients with ROS1+ #NSCLC. Learn more: https://t.co/OWMTnr4v4F. https://t.co/WoWRj7vNGD